Yuflyma™
INN: adalimumab
Approved for use in:
Crohn’s Disease (moderate-severe)
Ulcerative Colitis (moderate-severe)
Type/Class
Biosimilar
Delivery Route
Subcutaneous Injection
Health Canada Approval
2021
Storage
Refrigerate between 2 and 8°C, do not freeze, keep in original carton to protect from light, may be stored at room temperature (up to 25°C) for a single period of up to 30 days.
Use in Older Adults (65+)
May be used, please consult your doctor.
Pregnancy Indication
No pattern of major birth defects has been observed; infants may be at increased risk for infection.
Breastfeeding Indication
Low exposure levels due to large molecule size and degradation by GI tract.
Pediatric Indication
Not used for pediatric IBD.
Learn More
View the Yuflyma™ product monograph.